Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells

International Journal of Cancer

Volumn 98, Issue 5, 2002, Pages 656-664

  Nielsen, Boye Schnack ^a   Rank, Fritz ^b   Engelholm, Lars H ^a   Holm, Arne ^c   Danø, Keld ^a   Behrendt, Niels ^a  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Breast tumor; Endo180; Immunohistochemistry; uPARAP

Indexed keywords

MESSENGER RNA; PEPTIDE ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; UROKINASE RECEPTOR ASSOCIATED PROTEIN;

ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; BREAST LESION; CANCER CELL; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MYOEPITHELIUM CELL; MYOFIBROBLAST; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD31; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CROSS-LINKING REAGENTS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU HYBRIDIZATION; MANNOSE-BINDING LECTINS; MEMBRANE GLYCOPROTEINS; RABBITS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; STROMAL CELLS; TRANSCRIPTION, GENETIC; U937 CELLS;

EID: 0037051665     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10227     Document Type: Article

References (64)

1. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion
2. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types
3. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and -dependent pathways
4. Functional overlap between two classes of matrix-degrading proteases in wound healing
5. Lactational competence and involution of the mouse mammary gland require plasminogen
6. Matrix metalloproteinases: Biologic activity and clinical implications
7. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice
8. Impaired wound healing in mice with a disrupted plasminogen gene
9. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos
10. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
11. Metalloproteinases and tissue damage
12. Mechanisms for pro matrix metalloproteinase activation
13. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity
14. Plasminogen activator inhibitors: Hormonally regulated serpins
15. Gene targeting in hemostasis. Alpha2-antiplasmin
16. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator
17. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts
18. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
19. Prevention of metastasis by inhibition of the urokinase receptor
20. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
21. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth
22. Identification of the urokinase receptor as an adhesion receptor for vitronectin
23. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction
24. Regulation of integrin function by the urokinase receptor
25. Purified alpha2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type 1 complex. Evidence that the alpha2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes
26. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin
27. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity
28. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking
29. A urokinase receptor-associated protein with specific collagen binding properties
30. The urokinase receptor associated protein (uPARAP/Endo180): A novel internalization receptor connected to the plasminogen activation system
31. The mannose receptor is a pattern recognition receptor involved in host defense
32. Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor
33. p180, a novel recycling transmembrane glycoprotein with restricted cell type expression
34. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes
35. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
36. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer
37. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue
38. Messenger RNA for urokinase plasminogen activator (uPA) is expressed in myofibroblasts adjacent to cancer cells in human breast cancer
39. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer
40. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma
41. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain
42. Solid-phase peptide synthesis on proteins
43. Cellular receptor for urokinase-type plasminogen activator: Protein structure
44. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains
45. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
46. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
47. Histological grading and prognosis in breast cancer
48. Ductal carcinoma in situ: A proposal for a new classification
49. Synthesis of cRNA probes from PCR-generated DNA
50. Collagenase-3 (MMP-13) expression in breast myofibroblasts as a molecular marker of transition of DCIS lesions to invasive ductal carcinomas
51. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction
52. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization
53. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors
54. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation
55. Characterization of a novel member of the macrophage mannose receptor type C lectin family
56. The urokinase plasminogen activator receptor-associated protein/Endo180 is coexpressed with its interaction partners uPAR and matrix metalloproteinase-13 during osteogenesis
57. The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism
58. Myoepithelium in salivary and mammary neoplasms is host-friendly
59. The myoepithelial defense: A host defense against cancer
60. The human myoepithelial cell is a natural tumor suppressor
61. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. An immunocytochemical study
62. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues
63. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: An in situ hybridization study
64. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression